OLDWICK, N.J., Feb. 13, 2019 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical
company dedicated to developing novel therapeutics aimed at
intercepting and preventing immune-mediated diseases, announced
today its Chief Executive Officer, Ashleigh
Palmer, along with other members of Provention's executive
management team, will participate in a fireside chat presentation
at the 8th Annual Leerink Partners Global Healthcare
Conference being held February 27-March 1,
2019, at the Lotte New York Palace in New York City.
Details of Provention's presentation are as follows:
Conference:
|
8th Annual
Leerink Partners Global Healthcare Conference
|
Date:
|
Wednesday, February
27, 2019
|
Time:
|
11:00 am
(ET)
|
Location:
|
Lotte New York
Palace, New York; Track 6 - Louis, 4th Floor
|
An audio webcast will be accessible via the Events and Webcasts
section of the Provention Bio website:
http://investors.proventionbio.com/events. An archive of the audio
will remain available for 90 days following the presentation.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy that is
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to in-license, transform and
develop therapeutic candidates targeting the high morbidity,
mortality and escalating costs of autoimmune and inflammatory
diseases including: type 1 diabetes (T1D), Crohn's disease,
ulcerative colitis, celiac disease, lupus, and certain
life-threatening viral diseases. Provention's diversified portfolio
includes advanced-stage product development candidates that have
undergone clinical testing by other companies. For more information
on Provention Bio, please visit www.proventionbio.com.
Forward Looking Statements
Certain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, risks related to failure to obtain FDA approvals or
clearances and noncompliance with FDA regulations; uncertainties of
patent protection and litigation; limited research and development
efforts and dependence upon third parties; substantial competition;
our need for additional financing and the risks listed under "Risk
factors" in our quarterly report on Form 10-Q for the quarter ended
September 30, 2018 and any subsequent
filings with the Securities and Exchange Commission (SEC). As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Provention does not undertake an obligation to update
or revise any forward-looking statement. The information set forth
herein speaks only as of the date hereof.
Media & Investor Contacts
Jason Rando / Joshua
Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
T: 212 375 2665 / 212 375 2664
jrando@tiberend.com
jdrumm@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-8th-annual-leerink-partners-global-healthcare-conference-300794620.html
SOURCE Provention Bio, Inc.